Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr Hunter on the Development of Targeted Approaches Beyond JAK Inhibition in Myelofibrosis

January 16th 2025

Anthony M. Hunter, MD, discusses the development of, and future roles for JAK, BET, and BCL2/BCL-XL inhibitors in myelofibrosis.

Novel Agents May Enhance JAK Inhibitor Efficacy and Augment the Myelofibrosis Treatment Paradigm

January 10th 2025

Naseema Gangat, MBBS, discusses clinical factors that she uses to choose the optimal JAK inhibitors for individual patients with myelofibrosis.

Dr Eckfeldt on the Treatment Paradigm and Current Challenges in MDS

January 9th 2025

Craig Eckfeldt, MD, PhD, discusses the current treatment paradigm in MDS and the unmet needs in different subsets of patients.

Flonoltinib Maleate Provides Durable Spleen Reduction and Symptom Improvement in Myelofibrosis

January 7th 2025

Flonoltinib maleate generated rapid clinical benefits, including spleen volume reduction and symptom improvement, for patients with myelofibrosis.

Luspatercept/Lenalidomide Combo Demonstrates Safety and Early Efficacy in Lower-Risk, Non-Del(5q) MDS

January 7th 2025

Lenalidomide plus luspatercept demonstrated safety, tolerability, and efficacy in patients with non-del(5q) myelodysplastic syndrome.

Second-Line Ropeginterferon Alfa-2b Boosts Responses in Essential Thrombocythemia

January 6th 2025

Ropeginterferon alfa-2b improved responses in patients with essential thrombocythemia with resistance or intolerance to hydroxyurea.

Imetelstat Plus Ruxolitinib Demonstrates Tolerable Safety Profile in Myelofibrosis

January 6th 2025

Imetelstat plus ruxolitinib showed early tolerability and efficacy in patients with intermediate and high-risk myelofibrosis.

Treatment Trends: JAK Inhibitor Selection in Myelofibrosis

December 20th 2024

Sangeetha Venugopal, MD, MS, discusses factors that inform JAK inhibitor selection in myelofibrosis.

Dissecting the Current Treatment Landscape in MDS

December 18th 2024

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.

OB756 Showcases Favorable Tolerability in JAK Inhibitor–Naive Myelofibrosis

December 16th 2024

An investigative JAK2 inhibitor demonstrated acceptable tolerability and early clinical activity in patients with JAK inhibitor–naive myelofibrosis.

JAB-8263 Monotherapy Demonstrates Early Promise in Myelofibrosis

December 13th 2024

JAB-8263 given at once-daily doses ranging from 0.125 mg to 0.3 mg proved to be well tolerated in patients with myelofibrosis.

CHMP Offers Positive Opinion for Imetelstat for Transfusion-Dependent Anemia in Lower-Risk MDS

December 13th 2024

The EMA’s CHMP has recommended the approval of imetelstat for transfusion-dependent anemia in lower-risk myelodysplastic syndrome.

NFKB1 Haplotype Decreases Inflammation, Increases Response to Ropeginterferon Alfa-2b in PV and ET

December 11th 2024

NFKB1 rs230511 reduces inflammation and amplifies responses to ropeginterferon alfa-2b in polycythemia vera and essential thrombocythemia.

Dr Sekeres on Luspatercept Plus Lenalidomide in Non–5q Deletion MDS

December 9th 2024

Mikkael A. Sekeres, MD, discusses the results of combining luspatercept and lenalidomide in lower-risk, non–5q deletion myelodysplastic syndromes.

Navtemadlin Reduces Markers of Disease Burden in Relapsed/Refractory Myelofibrosis

December 9th 2024

Treatment with navtemadlin lowered the levels of biomarkers of disease burden in patients with relapsed/refractory myelofibrosis.

Highlights in MPNs, CLL With Drs Prithviraj Bose and Javier Pinilla Ibarz

December 9th 2024

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, and Javier Pinilla Ibarz, MD, PhD, of Moffitt Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest in myeloproliferative neoplasms and chronic lymphocytic leukemia, respectively, from the 2024 ASH Annual Meeting.

Smoking May Increase Genetic Mutations, Disease Progression in MDS

December 7th 2024

Findings showed the potential impact of smoking on disease progression and survival in patients with myelodysplastic syndrome.

Dr Watts on the Potential Advantages of INCB057643 in Advanced Myelofibrosis

November 27th 2024

Justin M. Watts, MD, discusses the potential advantages of the oral small molecule BET inhibitor INCB057643 in advanced myelofibrosis.

Dr Grunwald on Monitoring Risk Factors for Disease Progression in PV

November 20th 2024

Michael R. Grunwald, MD, discusses the importance of monitoring risk factors associated with disease progression in patients with polycythemia vera.

Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML

November 15th 2024

Venetoclax plus 10-day decitabine was safe and produced responses in AML and high-risk MDS.